- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Candel Therapeutics Inc (CADL)
Track today's live Candel Therapeutics (CADL) share price, performance and key data on this page with our current NASDAQ:CADL stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Candel Therapeutics share price on the NASDAQ exchange. Use the dropdown to switch exchange for the CADL share price, head to our technical summary section, which provides analysis on Candel Therapeutics share price buy/sell indicators using real-time data (or discuss the Candel Therapeutics (CADL) stock price today with other investors in the Candel Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:CADL share price (ISIN: US1374041093) to enhance your trading decisions with our free investment tools and resources.
What Is the Candel Therapeutics Inc Share Price Today?
The Candel Therapeutics share price today is 9.86.
What Is the Stock Symbol for Candel Therapeutics Inc
The stock symbol (or 'ticker') for Candel Therapeutics Inc is "CADL."
What Stock Exchange Does Candel Therapeutics Inc Trade On?
Candel Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Candel Therapeutics Inc a Good Stock to Buy?
Determining whether Candel Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:CADL share price (ISIN: US1374041093) to enhance your trading decisions with our free investment tools and resources.
What Is the Candel Therapeutics Inc Share Price Today?
The Candel Therapeutics share price today is 9.86.
What Is the Stock Symbol for Candel Therapeutics Inc
The stock symbol (or 'ticker') for Candel Therapeutics Inc is "CADL."
What Stock Exchange Does Candel Therapeutics Inc Trade On?
Candel Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Candel Therapeutics Inc a Good Stock to Buy?
Determining whether Candel Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.38
9.95
52 wk Range
4.35
11.36
CADL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.389.95
52 wk Range
4.3511.36
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CADL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
20.50
Upside
+107.91%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Form 4 Candel Therapeutics Inc For: 1 July- Investing.com
Form 4 Candel Therapeutics Inc For: 8 July- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 20.50
(+107.91% Upside)
Earnings
Latest Release
14/05/2026
EPS / Forecast
-0.14 / -0.34
Revenue / Forecast
-- / --
Compare CADL to Peers and Sector
Metrics to compare | CADL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCADLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.6x | −4.0x | −0.3x | |
PEG Ratio | −1.30 | 0.01 | 0.00 | |
Price/Book | 5.0x | 1.7x | 2.6x | |
Price / LTM Sales | - | 19.1x | 2.9x | |
Upside (Analyst Target) | 139.4% | 137.6% | 56.7% | |
Fair Value Upside | Unlock | 8.7% | 10.2% | Unlock |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Candel Therapeutics (NASDAQ: CADL) Share Price Today?
The Candel Therapeutics stock price today is 9.86 USD.
What Stock Exchange Does Candel Therapeutics (CADL) Trade On?
Candel Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Candel Therapeutics?
The stock symbol (also called a 'ticker') for Candel Therapeutics is "CADL."
What Is the Current Candel Therapeutics Market Capitalisation?
As of today, Candel Therapeutics (NASDAQ: CADL) market cap is 688.74M USD.
What Is Candel Therapeutics's (CADL) Earnings Per Share (TTM)?
The Candel Therapeutics EPS is currently -0.97 (Trailing Twelve Months).
When Is the Next Candel Therapeutics Earnings Date?
Candel Therapeutics's next earnings report will be released on 19/08/2026.
Is CADL a Buy or Sell From a Technical Analyst Perspective?
Based on today's Candel Therapeutics moving averages and other technical indicators, the daily buy/sell signal for CADL stock is Neutral.
How Many Times Has Candel Therapeutics Stock Split?
Candel Therapeutics has split 0 times. (See the CADL stock split history page for full effective split date and price information.)
How Many Employees Does Candel Therapeutics Have?
Candel Therapeutics has 55 employees, based on their latest Companies House report.
What is the current trading status of Candel Therapeutics (NASDAQ: CADL)?
As of 30/07/2026, Candel Therapeutics (CADL) is trading at a share price of 9.86 USD, with a previous close of 9.40 USD. The stock has fluctuated within a day range of 9.38 USD to 9.95 USD, while its 52-week range spans from 4.35 USD to 11.36 USD.
What Is Candel Therapeutics (CADL) Price Target According to Analysts?
The average 12-month price target for Candel Therapeutics is 20.50 USD, with a high estimate of 29 USD and a low estimate of 9 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +107.91% Upside potential.
What Is the CADL Premarket Price?
CADL's last pre-market stock price is 9.36 USD. The pre-market share volume is 8,050.00, and the stock has decreased by -0.04, or -0.43%.
What Is the CADL After Hours Price?
CADL's last after hours stock price is 9.86 USD, the stock has decreased by -0.01, or -0.08%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.